Evercore ISI upgraded Edwards Lifesciences (EW) to Outperform from In Line with a price target of $88, up from $80. Competitive fears have abated and the firm sees a potential inflection in TAVR procedures, driven by asymptomatic TAVR, the analyst tells investors. The firm identifies the moderate AS trial readout as another potential positive catalyst.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Edwards Lifesciences price target lowered to $85 from $95 at Stifel
- Edwards Lifesciences management to meet with Piper Sandler
- Edwards Lifesciences: Strategic Positioning and Growth Potential Drive Buy Rating Amid TAVR Market Expansion
- Edwards Lifesciences Enters Accelerated Share Repurchase Agreement
- Edwards Lifesciences announces $500M accelerated share repurchase